Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 8/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.71 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.55 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450269 | 1.00 | CHRNB4 (0.71) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4364278 | 1.00 | CHRNB4 (0.71) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL6217227 | 0.91 | CHRNB4 (0.59) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL6225147 | 0.85 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4098323 | 0.85 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL446091 | 0.82 | CHRNB4 (0.48) | CHRNB4CHRNA3FAAH | |
| SCHEMBL1264856 | 0.82 | CHRNB4 (0.48) | CHRNB4CHRNA3FAAH | |
| SCHEMBL447282 | 0.82 | CHRNB4 (0.48) | CHRNB4CHRNA3FAAH | |
| SCHEMBL28735299 | 0.82 | CHRNB4 (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL15037237 | 0.81 | CHRNB4 (0.61) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478366-A | Pyridone derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | CHRNB4 4745/4885CHRNA3 4728/4885CHRNB2 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.